Takeda, Zinfandel link may revive ACTOS in Alzheimer's disease
This article was originally published in Scrip
Takeda became the latest of the major pharmaceutical companies to turn to biomarker-based diagnostics its approach to Alzheimer’s disease when it signed an exclusive, worldwide licensing agreement with Zinfandel Pharmaceuticals on the development of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease. However, recently published research elsewhere suggests that a full understanding of the biology of the disease may not be necessary in identifying potential Alzheimer's diagnostics.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.